Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of endocrine ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its ...
Cystic fibrosis is among the most common, known and studied genetic diseases. It affects over 100,000 people worldwide and ...
Life science company Bio-Rad Laboratories has extended its range of recombinant monoclonal anti -idiotypic antibodies. The ...
A graph-based computational tool for detecting previously invisible genetic mutations has been developed. Researchers at the University of California, Los Angeles (UCLA; USA) and the University of ...
A new long-read sequencing technique has helped researchers investigate how DNA mutations arise in a variety of contexts. A collaboration of researchers led by NYU Langone Health and NYU Grossman ...
It’s well established that some cases of amyotrophic lateral sclerosis (ALS) are caused by mutations that are inherited from a person’s parents — but a new study shows some cases of sporadic ALS may ...
Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In ...
MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results